date:Oct 16, 2013
erform a risk assessment on (-)-hyoscyamine and (-)-scopolamine, the two TAs for which occurrence and toxicity data were available. Since the pharmacological effects of (-)-hyoscyamine and (-)-scopolamine occur within a short time after administration, the CONTAM Panel concluded that it was appropriate to establish an Acute Reference Dose (ARfD) for these substances.
Based on the results for decreased heart rate in a human volunteer study, the CONTAM Panel established a group ARfD of 0.016 g/kg